In vitro models demonstrate the potential of monocyte-derived hepatocyte-like cells in investigating drug-induced liver injury mechanisms, suggesting a shift from animal testing.
Developing in vitro models that incorporate immunological aspects of iDILI susceptibility is essential for advancing hepatotoxicity research as an alternative to animal testing, aligning with the Food and Drug Administration (FDA) Modernization Act 2.0. Peripheral blood monocyte-derived hepatocyte-like cells, particularly when incorporated into multicellular organoid systems, offer a valuable opportunity to mimic the polygenic architecture of drug susceptibility, enabling the investigation of a compound's DILI potential and underlying mechanisms.
No takes yet. Share an insight, caveat, or question.
Vargas et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: